Association of Tumor Necrosis Factor-Alpha with Psychopathology in Patients with Schizophrenia.
immune system
psychopathology
schizophrenia
tumor necrosis factor-alpha
Journal
Acta medica Okayama
ISSN: 0386-300X
Titre abrégé: Acta Med Okayama
Pays: Japan
ID NLM: 0417611
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
27
8
2023
Statut:
ppublish
Résumé
We investigated the relationship between serum tumor necrosis factor-alpha (TNF-α) levels and psychopathological symptoms, clinical and socio-demographic characteristics and antipsychotic therapy in individuals with schizophrenia. TNF-α levels were measured in 90 patients with schizophrenia and 90 healthy controls matched by age, gender, smoking status, and body mass index. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of psychopathology in patients. No significant differences in TNF-α levels were detected between the patients and controls (p=0.736). TNF-α levels were not correlated with total, positive, negative, general, or composite PANSS scores (all p>0.05). A significant negative correlation was observed between TNF-α levels and the PANSS cognitive factor (ρ=-0.222, p=0.035). A hierarchical regression analysis identified the cognitive factor as a significant predictor of the TNF-α level (beta=-0.258, t=-2.257, p=0.027). There were no significant differences in TNF-α levels among patients treated with different types of antipsychotics (p=0.596). TNF-α levels correlated positively with the age of onset (ρ=0.233, p=0.027) and negatively with illness duration (ρ=-0.247, p=0.019) and antipsychotic treatment duration (ρ=-0.256, p=0.015). These results indicate that TNF-α may be involved in cognitive impairment in schizophrenia, and would be a potential clinical-state marker in schizophrenia.
Substances chimiques
Antipsychotic Agents
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-405Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Owen MJ, Sawa A and Mortensen PB: Schizophrenia. Lancet (2016) 388: 86-97.
Silveira C, Marques-Teixeira J and de Bastos-Leite AJ: More than one century of schizophrenia: an evolving perspective. J Nerv Ment Dis (2012) 200: 1054-1057.
Marder SR and Cannon TD: Schizophrenia. N Engl J Med (2019) 381: 1753-1761.
Zamanpoor M: Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatr Genet (2020) 30: 1-9.
Müller N: Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. Schizophr Bull (2018) 44: 973-982.
Fan X, Goff DC and Henderson DC: Inflammation and schizophrenia. Expert Rev Neurother (2007) 7: 789-796.
Müller N, Riedel M, Gruber R, Ackenheil M and Schwarz MJ: The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci (2000) 917: 456-467.
Kirch DG: Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull (1993) 19: 355-370.
Müller N, Myint AM and Schwarz MJ: Inflammation in schizophrenia. Adv Protein Chem Struct Biol (2012) 88: 49-68.
Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ and Leonard BE: Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 28: 1129-1134.
Monji A, Kato T and Kanba S: Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci (2009) 63: 257-265.
Cho M, Lee TY, Kwak YB, Yoon YB, Kim M and Kwon JS: Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry (2019) 53: 742-759.
Reale M, Costantini E and Greig NH: Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. Front Psychiatry (2021) 12: 536257.
Miller BJ, Buckley P, Seabolt W, Mellor A and Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry (2011) 70: 663-671.
Drexhage RC, Weigelt K, van Beveren N, Cohen D, Versnel MA, Nolen WA and Drexhage HA: Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol (2011) 101: 169-201.
Goldsmith DR, Rapaport MH and Miller BJ: A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry (2016) 21: 1696-1709.
Drzyzga L, Obuchowicz E, Marcinowska A and Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun (2006) 20: 532-545.
Girgis RR, Kumar SS and Brown AS: The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry (2014) 75: 292-299.
Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R and Jones PB: Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry (2015) 2: 258-270.
Tracey D, Klareskog L, Sasso EH, Salfeld JG and Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2008) 117: 244-279.
Montgomery SL and Bowers WJ: Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol (2012) 7: 42-59.
Probert L: TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience (2015) 302: 2-22.
OʼBrien SM, Scully P and Dinan TG: Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res (2008) 160: 256-262.
Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L, Murray RM, Dazzan P, Pariante CM and Mondelli V: Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun (2013) 31: 90-95.
Naudin J, Capo C, Giusano B, Mège JL and Azorin JM: A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res (1997) 26: 227-233.
Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A, Poznanovic ST, Jovanovic A, Nikolic T and Petronijevic ND: Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr Danub (2013) 25: 55-61.
Lv MH, Tan YL, Yan SX, Tian L, Chen da C, Tan SP, Wang ZR, Yang FD, Yoon JH, Zunta-Soares GB, Soares JC and Zhang XY: Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition. Psychopharmacology (Berl) (2015) 232: 165-172.
Tian L, Tan Y, Chen D, Lv M, Tan S, Soares JC and Zhang XY: Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry (2014) 54: 259-264.
Xu HM, Wei J and Hemmings GP: Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry (1994) 164: 251-253.
Erbağci AB, Herken H, Köylüoglu O, Yilmaz N and Tarakçioglu M: Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm (2001) 10: 109-115.
Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A and Falkai P: Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat (2005) 1: 171-177.
Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME and Teixeira AL: Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation (2008) 15: 140-144.
Momtazmanesh S, Zare-Shahabadi A and Rezaei N: Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry (2019) 10: 892.
Pandey GN, Rizavi HS, Zhang H and Ren X: Abnormal gene and protein expression of inflammatory cytokines in the postmortem brain of schizophrenia patients. Schizophr Res (2018) 192: 247-254.
Zhu Y, Owens SJ, Murphy CE, Ajulu K, Rothmond D, Purves-Tyson T, Middleton F, Webster MJ and Weickert CS: Inflammation-related transcripts define “high” and “low” subgroups of individuals with schizophrenia and bipolar disorder in the midbrain. Brain Behav Immun (2022) 105: 149-159.
Pandey GN, Ren X, Rizavi HS and Zhang H: Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients. Schizophr Res (2015) 164: 193-198.
Na KS and Kim YK: Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology (2007) 56: 55-63.
Naz M, Riaz M and Saleem M: Potential role of Neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep (2011) 38: 4709-4714.
Suchanek-Raif R, Raif P, Kowalczyk M, Paul-Samojedny M, Kucia K, Merk W and Kowalski J: Polymorphic Variants of TNFR2 Gene in Schizophrenia and Its Interaction with -308G/A TNF-α Gene Polymorphism. Mediators Inflamm (2018) 2018: 8741249.
Srinivas L, Vellichirammal NN, Alex AM, Nair C, Nair IV and Banerjee M: Pro-inflammatory cytokines and their epistatic interactions in genetic susceptibility to schizophrenia. J Neuroinflammation (2016) 13: 105.
Sacchetti E, Bocchio-Chiavetto L, Valsecchi P, Scassellati C, Pasqualetti P, Bonvicini C, Corsini P, Rossi G, Cesana BM, Barlati S and Gennarelli M: -G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study. Brain Behav Immun (2007) 21: 450-457.
Zhu F, Zhang L, Liu F, Wu R, Guo W, Ou J, Zhang X and Zhao J: Altered Serum Tumor Necrosis Factor and Interleukin-1β in First-Episode Drug-Naive and Chronic Schizophrenia. Front Neurosci (2018) 12: 296.
Tourjman V, Kouassi É, Koué MÈ, Rocchetti M, Fortin-Fournier S, Fusar-Poli P and Potvin S: Antipsychoticsʼ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res (2013) 151: 43-47.
Lin C, Chen K, Yu J, Feng W, Fu W, Yang F, Zhang X and Chen D: Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients. BMC Psychiatry (2021) 21: 561.
Capuzzi E, Bartoli F, Crocamo C, Clerici M and Carrà G: Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: A meta-analysis. Neurosci Biobehav Rev (2017) 77: 122-128.
Romeo B, Brunet-Lecomte M, Martelli C and Benyamina A: Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis. Int J Neuropsychopharmacol (2018) 21: 828-836.
Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kühn M, Schuld A and Pollmächer T: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res (1999) 33: 407-418.
Turhan L, Batmaz S, Kocbiyik S and Soygur AH: The role of tumour necrosis factor alpha and soluble tumour necrosis factor alpha receptors in the symptomatology of schizophrenia. Nord J Psychiatry (2016) 70: 342-350.
Miller BJ and Goldsmith DR: Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder. Focus (Am Psychiatr Publ) (2020) 18: 391-401.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R and Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 59 Suppl 20: 22-57.
Kay SR, Fiszbein A and Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 13: 261-276.
Lehoux C, Gobeil MH, Lefèbvre AA, Maziade M and Roy MA: The Five-Factor Structure of the PANSS: A Critical Review of its Consistency Across Studies. Clin Schizophr Relat Psychoses (2009) 3: 103-110.
Citrome L, Meng XY and Hochfeld M: Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res (2011) 131: 75-81.
Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR and Dickinson D: Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res (2012) 137: 246-250.
Baker I, Masserano J and Wyatt RJ: Serum cytokine concentrations in patients with schizophrenia. Schizophr Res (1996) 20: 199-203.
Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-SantʼAnna M, Kapczinski F and Gama CS: Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Braz J Psychiatry (2011) 33: 268-274.
Dunjić-Kostić B: The significance of interleukin-6 and tumor necrosis factor-alpha levels in patients with schizophrenia [Dissertation]. University of Belgrade, Belgrade (2013) (in Serbian).
Ribeiro-Santos A, Lucio Teixeira A and Salgado JV: Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol (2014) 12: 273-280.
Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, Jacobsen SE and Lindvall O: Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci (2006) 26: 9703-9712.
Garay PA and McAllister AK: Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front Synaptic Neurosci (2010) 2: 136.
Medina S, Martínez M and Hernanz A: Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res (2002) 36: 1179-1184.
Buntinx M, Moreels M, Vandenabeele F, Lambrichts I, Raus J, Steels P, Stinissen P and Ameloot M: Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J Neurosci Res (2004) 76: 834-845.
Baek SH, Kim H, Kim JW, Ryu S, Lee JY, Kim JM, Shin IS and Kim SW: Association between Peripheral Inflammatory Cytokines and Cognitive Function in Patients with First-Episode Schizophrenia. J Pers Med (2022) 12: 1137.
Kogan S, Ospina LH and Kimhy D: Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function. Brain Behav Immun (2018) 74: 296-299.
Chukaew P, Bunmak N, Auampradit N, Siripaiboonkij A, Saengsawang W and Ratta-Apha W: Correlation of BDNF, VEGF, TNF-α, and S100B with cognitive impairments in chronic, medicated schizophrenia patients. Neuropsychopharmacol Rep (2022) 42: 281-287.
Ergün S, Yanartaş Ö, Kandemir G, Yaman A, Yıldız M, Haklar G and Sayar K: The relationship between psychopathology and cognitive functions with cytokines in clinically stable patients with schizophrenia. Psychiatr Clin Psychopharmacol (2018) 28: 66-72.
Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y and Nakamura J: Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World J Biol Psychiatry (2017) 18: 401-408.
Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Wu HE, Zunta-Soares GB, Huang XF, Kosten TR and Soares JC: Interaction of BDNF with cytokines in chronic schizophrenia. Brain Behav Immun (2016) 51: 169-175.
Miller BJ and Goldsmith DR: Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology. Biomark Neuropsychiatry (2019) 1: 100006.
Nielsen RE, Lindström E, Telléus GK and Levander S: Is the PANSS cognitive scale measuring cognition? Nord J Psychiatry (2014) 68: 573-578.
Pollmächer T, Hinze-Selch D and Mullington J: Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol (1996) 16: 403-409.
Monteleone P, Fabrazzo M, Tortorella A and Maj M: Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res (1997) 71: 11-17.
Phan SV: Medication adherence in patients with schizophrenia. Int J Psychiatry Med (2016) 51: 211-219.
Born J, Uthgenannt D, Dodt C, Nünninghoff D, Ringvolt E, Wagner T and Fehm HL: Cytokine production and lymphocyte subpopulations in aged humans. An assessment during nocturnal sleep. Mech Ageing Dev (1995) 84: 113-126.
Lee EE, Hong S, Martin AS, Eyler LT and Jeste DV: Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. Am J Geriatr Psychiatry (2017) 25: 50-61.
Tsuneyama N, Suzuki Y, Sawamura K, Sugai T, Fukui N, Watanabe J, Ono S, Saito M and Someya T: Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. PLoS One (2016) 11: e0149518.
Isuru A and Rajasuriya M: Tobacco smoking and schizophrenia: re-examining the evidence. BJPsych Adv (2019) 25: 363-372.
Friedman H, Pross S and Klein TW: Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol (2006) 47: 330-342.
Nuttall FQ: Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today (2015) 50: 117-128.
Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV and Rabin BS: Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res (1994) 51: 1-10.
Müller N and Schwarz MJ: Immune System and Schizophrenia. Curr Immunol Rev (2010) 6: 213-220.
Rajji TK, Ismail Z and Mulsant BH: Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry (2009) 195: 286-293.
Goonathilake P, Ediriweera D, Ruban R and Isuru A: Prevalence and correlates of cognitive impairment in schizophrenia: a cross-sectional study from a teaching hospital southern Sri Lanka. BMC Psychiatry (2022) 22: 716.
Zhang JM and An J: Cytokines, inflammation, and pain. Int Anesthesiol Clin (2007) 45: 27-37.
Manu P, Correll CU, Wampers M, Mitchell AJ, Probst M, Vancampfort D and De Hert: Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry (2014) 13: 189-192.
Giugliano D, Ceriello A and Esposito K: The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol (2006) 48: 677-685.
Aziz N: Measurement of Circulating Cytokines and Immune-Activation Markers by Multiplex Technology in the Clinical Setting: What Are We Really Measuring? For Immunopathol Dis Therap (2015) 6: 19-22.